Latest Regulatory Update News

Page 1 of 6
Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.
Ada Torres
Ada Torres
29 Oct 2026
EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.
Victor Sage
Victor Sage
20 Oct 2026
ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.
Victor Sage
Victor Sage
14 Oct 2026
Southern Cross Gold has accelerated drilling and underground development at Sunday Creek, spending $32.9 million during the August quarter while cash fell to C$84.0 million. The company remains aimed at a maiden mineral resource in the first quarter of 2027, but poor ground conditions have pushed exploration decline completion back by a month.
Maxwell Dee
Maxwell Dee
8 Oct 2026
EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.
Victor Sage
Victor Sage
16 Sept 2026
Aurizon lifted FY2026 underlying EBITDA by 9% to $1.72 billion, boosted by strong Bulk growth and regulatory gains, while locking in a major Queensland coal haulage contract with BHP Mitsubishi Alliance.
Victor Sage
Victor Sage
17 Aug 2026
Novatti Group Limited delivered a 5% quarter-on-quarter revenue increase to $7.6 million in Q4 FY26, driven by its Payments AU/NZ segment's strong 8% revenue and 26% margin growth. The company achieved positive EBITDA of $0.3 million, boosted by a 95% jump in Payments AU/NZ EBITDA to $0.9 million.
Claire Turing
Claire Turing
31 July 2026
Predictive Discovery reported a 33% increase in gold production to 64,026 ounces in Q2 2026, driven by Kiniero’s operational ramp-up and advancing development at the Bankan project.
Maxwell Dee
Maxwell Dee
30 July 2026
Solis Minerals has secured a strategic lithium asset in Brazil's Araçuaí–Salinas Lithium Valley and initiated drilling at Mandacaru, while advancing copper projects in Peru with fresh capital backing.
Maxwell Dee
Maxwell Dee
29 July 2026
Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.
Ada Torres
Ada Torres
29 July 2026
Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.
Maxwell Dee
Maxwell Dee
28 July 2026
AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.
Victor Sage
Victor Sage
21 July 2026

Browse the archive

Full archive